Inovio price target lowered to $5 from $6 at RBC Capital
RBC Capital lowered the firm’s price target on Inovio (INO) to $5 from $6 and keeps a Sector Perform rating on the shares. The company ...
Nature5y
Neurodevelopmental and Respiratory Outcomes at 2 Years of Age in Preterm Infants Treated with Inhaled Nitric Oxide: the Euno Trial Follow Up
Methods: Babies < 29 weeks of gestation with moderate respiratory failure in the first 24 hours after birth were randomly allocated iNO 5 ppm for 7 to 21 days or placebo gas. All babies were ...
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
Inovio Pharmaceuticals Inc. closed 86.91% short of its 52-week high of $14.75, which the company reached on April 1st.
Yahoo Finance6d
Inovio Pharmaceuticals, Inc. (INO)
INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...